- Home
- CSPI vs ACRS Comparison
CSPI vs ACRS Comparison
Compare CSPI & ACRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CSPI
- ACRS
- Stock Information
- Founded
- CSPI 1968
- ACRS 2012
- Country
- CSPI United States
- ACRS United States
- Employees
- CSPI N/A
- ACRS N/A
- Industry
- CSPI EDP Services
- ACRS Biotechnology: Pharmaceutical Preparations
- Sector
- CSPI Technology
- ACRS Health Care
- Exchange
- CSPI Nasdaq
- ACRS Nasdaq
- Market Cap
- CSPI 128.4M
- ACRS 132.0M
- IPO Year
- CSPI 1987
- ACRS 2015
- Fundamental
- Price
- CSPI $12.91
- ACRS $2.05
- Analyst Decision
- CSPI
- ACRS Hold
- Analyst Count
- CSPI 0
- ACRS 4
- Target Price
- CSPI N/A
- ACRS $1.00
- AVG Volume (30 Days)
- CSPI 16.2K
- ACRS 1.3M
- Earning Date
- CSPI 12-10-2024
- ACRS 11-06-2024
- Dividend Yield
- CSPI 0.93%
- ACRS N/A
- EPS Growth
- CSPI N/A
- ACRS N/A
- EPS
- CSPI 0.27
- ACRS N/A
- Revenue
- CSPI $57,512,000.00
- ACRS $27,079,000.00
- Revenue This Year
- CSPI N/A
- ACRS N/A
- Revenue Next Year
- CSPI N/A
- ACRS N/A
- P/E Ratio
- CSPI $47.35
- ACRS N/A
- Revenue Growth
- CSPI N/A
- ACRS 26.35
- 52 Week Low
- CSPI $8.22
- ACRS $0.77
- 52 Week High
- CSPI $29.93
- ACRS $2.72
- Technical
- Relative Strength Index (RSI)
- CSPI 52.22
- ACRS 55.69
- Support Level
- CSPI $12.41
- ACRS $2.09
- Resistance Level
- CSPI $13.00
- ACRS $2.72
- Average True Range (ATR)
- CSPI 0.47
- ACRS 0.26
- MACD
- CSPI 0.03
- ACRS -0.01
- Stochastic Oscillator
- CSPI 76.32
- ACRS 40.71
About CSPI CSP Inc.
CSP Inc along with its subsidiaries develops and markets IT integration solutions, security products, managed IT services, cloud services, purpose-built network adapters, and high-performance cluster computer systems. The firm operates in two segments namely Technology Solutions, where the company focus on value-added reseller integrated solutions including third-party hardware, software, and technical computer-related consulting, and High-Performance Products segments, where the company design, manufacture and deliver products and services to customers that require specialized cyber security services, networking and signal processing. It generates a majority of its revenue from the Technology Solutions segment. Geographically, the company generates its maximum revenue from the Americas.
About ACRS Aclaris Therapeutics Inc.
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing inventive therapies to address unmet needs for immuno-inflammatory diseases. The contract research segment earns revenue from the provision of laboratory services. The majority of its revenue comes from the contract research segment, which provides laboratory services. Its drug candidates under development are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138 is an ITJ Inhibitor; and ATI-1777.